Loading
A phase 1/2 trial of Pucotenlimab in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
OH2 Injection in Combination With HX008 for Melanoma. is a phase 1/2 interventional study registered as NCT04616443 by Binhui Biopharmaceutical Co., Ltd., with 60 participants planned, started 2020-12-01 and due to reach its primary completion in 2025-11-30. Interventions recorded: OH2 injection, HX008 injection. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Shares Binhui Biopharmaceutical, Melanoma.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.